A Nonribosomal Peptide Synthase Gene Driving Virulence in *Mycobacterium tuberculosis*

Kiranmai Bhatt,‡ Henrique Machado,¶ Nuno S. Osório,§ Jeremy Sousa,¶ Filipa Cardoso,¶ Carlos Magalhães,¶ Bing Chen,¶ Mei Chen,¶ John Kim,¶ Albel Singh,§ Catarina M. Ferreira,¶ António G. Castro,¶ Egidio Torrado,¶ William R. Jacobs, Jr.,¶,h Apoorva Bhatt,¶ Margarida Saraiva,¶,a

心内英格兰 NHS 信托，伯明翰，英国

ICVS，米尼奥大学，布拉加，葡萄牙

ICVS/3B’s—PT 政府附属实验室，布拉加，葡萄牙

3S—Instituto de Investigação e Inovação em Saúde，波尔图，葡萄牙

IBMC—Instituto de Biologia Molecular e Celular，波尔图大学，波尔图，葡萄牙

Department of Microbiology and Immunology，爱伯丁李士大学，纽约，纽约，美国

School of Biosciences and Institute of Microbiology and Infection，伯明翰大学，伯明翰，英国

Howard Hughes 医学研究所，爱伯丁李士大学，医学和感染学，纽约，纽约，美国

ABSTRACT Nonribosomal peptide synthases produce short peptides in a manner that is distinct from classical mRNA-dependent ribosome-mediated translation. The *Mycobacterium tuberculosis* genome harbors a nonribosomal peptide synthase gene, *nrp*，which is part of a gene cluster proposed to be involved in the biosynthesis of isonitrile lipopeptides. Orthologous clusters are found in other slow-growing pathogenic mycobacteria and actinomycetes. To probe the role of the *nrp* gene in infection, we generated a *nrp* deletion mutant in *M. tuberculosis* H37Rv and tested its virulence in immunocompetent (C57BL/6) mice. The *nrp* mutant strain displayed lower initial growth rates in the lungs and a defective dissemination to the spleens of infected mice. Mice infected with the mutant strain also survived for twice as long as those infected with wild-type *M. tuberculosis* and, remarkably, showed subdued pathology, despite similar bacterial loads at later stages of infection. The differences in the course of infection between wild-type and *nrp* mutant strains were accompanied by distinct dynamics of the immune response. Most strikingly, the *nrp* mutant was highly attenuated in immunodeficient (SCID-, recombination activating 2 [RAG2]-, and gamma interferon [IFN-γ]-deficient) mice, suggesting that macrophages control the *nrp* mutant more efficiently than they control the wild-type strain. However, in the presence of IFN-γ, both strains were equally controlled. We propose that the *nrp* gene and its associated cluster are drivers of virulence during the early stages of infection.

IMPORTANCE Over 10 million people developed tuberculosis (TB) in 2016, and over 1.8 million individuals succumbed to the disease. These numbers make TB the ninth leading cause of death worldwide and the leading cause from a single infectious agent. Therefore, finding novel therapeutic targets in *Mycobacterium tuberculosis*, the pathogen that causes most cases of human TB, is critical. In this study, we reveal a novel virulence factor in *M. tuberculosis*, the *nrp* gene. The lack of *nrp* highly attenuates the course of *M. tuberculosis* infection in the mouse model, which is particularly relevant in immune-deficient hosts. This is very relevant as TB is particularly incident in immune-suppressed individuals, such as HIV patients.

KEYWORDS immune deficiency, pathogenesis, tuberculosis, virulence factors

Received 20 July 2018 Accepted 6 October 2018 Published 31 October 2018 Citation Bhatt K, Machado H, Osório NS, Sousa J, Cardoso F, Magalhães C, Chen B, Chen M, Kim J, Singh A, Ferreira CM, Castro AG, Torrado E, Jacobs WR, Jr, Bhatt A, Saraiva M. 2018. A nonribosomal peptide synthase gene driving virulence in *Mycobacterium tuberculosis*. mSphere 3:e00352-18. https://doi.org/10.1128/mSphere.00352-18.

Editor Christina L. Stallings, Washington University in St. Louis School of Medicine

Copyright © 2018 Bhatt et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Address correspondence to Apoorva Bhatt, a.bhatt@bham.ac.uk, or Margarida Saraiva, margarida.saraiva@ibmc.up.pt.

KB, H.M., A.B., and M.S. contributed equally to this work.
Tuberculosis (TB) remains a leading cause of death by an infectious agent. Indeed, TB, caused by *Mycobacterium tuberculosis*, kills over 1.8 million people, affects over 10 million new individuals per year, and is estimated to exist in a latent form in one-fourth of the world’s population (1). To reach the milestone of less than one TB case per million individuals, set by the World Health Organization (WHO) for 2050, numerous roadblocks will have to be overcome, notably, the development of more efficient vaccines and therapies. Success on these fronts requires a greater understanding of the mechanisms underlying the success of *M. tuberculosis* as a pathogen. In this regard, a variety of genetic strategies have been employed to unlock novel virulence factors in *M. tuberculosis* and hence druggable targets (2–4).

Nonribosomal peptide synthases (NRPSs) are large multifunctional proteins involved in the biosynthesis of short peptides in a manner that is distinct from the ribosome-mediated translation of mRNA (5). The genes encoding NRPSs are predominantly found in bacteria and fungi that produce secondary metabolites (6). The short peptides produced by NRPSs usually form part of a larger more complex molecule. The genomes of mycobacteria, including the TB-causing *M. tuberculosis*, contain genes encoding NRPSs. While NRPSs in environmental bacteria are often associated with antibiotic and other secondary metabolite production (6), mycobacterial NRPSs are mainly involved in the production of components of complex cell wall lipids and siderophores (7, 8). *Rv0101* (*nrp*) is an *M. tuberculosis* H37Rv gene annotated as a NRPS (9). The gene encodes a putative bimodular NRPS containing seven catalytic domains (10, 11), including an adenylation domain with predicted substrate specificity for lysine and phenylalanine. *nrp* is located in a cluster of genes with potentially linked functions: *Rv0097* encodes a putative oxidase, *Rv0098* encodes a long-chain fatty acyl-coenzyme A (fatty acyl-CoA) thioesterase (12, 13), and FadD10 (*Rv0099*) is a fatty acyl-AMP ligase that catalyzes the transfer of fatty acyl chains to an acyl carrier protein encoded by *Rv0100* (10). The knowledge about the precise function of *nrp* and its associated cluster is based solely on the structural characterization and *in vitro* enzyme assays with heterologously expressed and purified *M. tuberculosis* and *Mycobacterium marinum* proteins and suggests a role in the production of a novel lipopeptide with isonitrile functionality (10, 14).

Importantly, several *in vitro* and *in vivo* infection studies have highlighted a potential role for *nrp* in the pathogenesis of TB. Specifically, *nrp* was reported as a nonessential gene for *in vitro* growth by transposon mutagenesis (15) but was otherwise required for growth in the spleens of C57BL/6J mice (16). Additionally, the gene cluster spanning *Rv0096*-*Rv0101* was shown to be critical for survival in mice (17). Furthermore, Nrp was reported to be the most abundant *M. tuberculosis* protein in the lungs of infected guinea pigs by day 30 postinfection, while being undetected at 90 days postinfection (18). Overall, these reports indicate that the cryptic metabolite produced by the *nrp* cluster is likely to play a role in virulence, which calls for a deeper investigation of *nrp* in the context of *M. tuberculosis* biology and infection.

In this study, we sought to query the role of the *nrp* gene in the pathogenesis of TB in the mouse model of infection. Our strategy consisted of the generation of *M. tuberculosis* mutant strains lacking the *nrp* gene. We herein reveal an important role for *nrp* in the virulence of *M. tuberculosis*, likely mediating the initial interaction of the bacteria with the host macrophages. We show that *nrp*-deficient *M. tuberculosis* grows at a lower rate in immunocompetent and immunodeficient mice, causing less lung pathology and associated with significantly increased survival rates.

**RESULTS**

*nrp* cluster in mycobacteria. The *M. tuberculosis* *nrp* gene (*Rv0101*) encodes a bimodular NRPS with domains predicted to activate Lys and Phe (10, 11, 14). The gene is present in a cluster of 5 genes including *nrp* plus *Rv0097* to *Rv0100*. A sequence comparison analysis of the *nrp* cluster among 72 genomes from species representative of the phylogeny of the genus *Mycobacterium* (19) revealed that this cluster is absent in most rapid-growing nontuberculous mycobacteria (NTM), commonly found in the...
environment and considered nonpathogenic (Fig. 1A). The NTM exceptions harboring genes of the nrp cluster with more than 40% identity score to the genes of M. tuberculosis were Mycobacterium peregrinum, Mycobacterium fortuitum, Mycobacterium mageritense, Mycobacterium tusciae, and Mycobacterium thermoresistible. Most slow-growing mycobacteria (31 of 48 [64.6%]) harbor orthologs to the M. tuberculosis Rv0097-Rv0101 genes with identity scores above 45% (Fig. 1A). This includes other pathogenic species, such as Mycobacterium leprae (50.6% identity) and Mycobacterium ulcerans (55.2% identity) (Fig. 1A). A synteny analysis showed that the nrp cluster is located in a homologous genomic DNA region shared by the chromosomes of the species of the Mycobacterium tuberculosis complex (MTBC) and M. leprae, without major sequence rearrangements. The exception is the considerably smaller size of the nrp gene in M. leprae compared to the nrp genes found in species from the MTBC (4,206 bp in M. leprae NC_002677 versus 7,539 bp in M. tuberculosis NC_000962) (Fig. 1B). As a result of this difference, the structural prediction is that the nrp gene found in MTBC strains encodes a bimodular NRPS, whereas the homologues from other mycobacteria, such as M. leprae, encode a single NRPS module. A detailed analysis of the level of nucleotide diversity of these genes within the MTBC was obtained by the analysis of 220 M. tuberculosis genomes from 7 MTBC lineages (20) and showed that the level

**FIG 1** The nrp cluster is highly conserved among the MTBC and slow-growing species of the genus Mycobacterium. (A) Sequence identity scores of the nrp cluster were obtained by querying the M. tuberculosis H37Rv sequences Rv0097-Rv0101 against a local database of 72 genomes of species representative of the phylogeny of the genus Mycobacterium (19). The genomics sequences include complete genomes and whole-genome shotgun sequences. The highest percentage (dark green) corresponds to the longest and most elevated sequence identities. (B) Synteny of the genome sections harboring the nrp cluster in M. tuberculosis, M. bovis, M. canettii, and M. leprae. The green shading indicate homologous DNA regions shared by the four chromosomes without major sequence rearrangements. The genes of the nrp cluster are highlighted in yellow. (C) Nucleotide diversity (π) level of the M. tuberculosis genes Rv0097, fcoT, fadD10, Rv0100, and nrp and the complete genome across a set of 220 genomes, including strains from lineage 1 to 7 of the MTBC.
of nucleotide diversity of these genes is below the genome-wide level (Fig. 1C). Thus, the comparative genome analysis suggests that the \( nrp \) cluster is highly conserved among slow-growing members of the \textit{Mycobacterium} genus, highlighting the larger size of the \( nrp \) gene as the most characteristic MTBC-associated feature.

**Loss of the \( nrp \) gene results in attenuation of \textit{M. tuberculosis} H37RV in mice.** To investigate the role of \( nrp \) in the virulence of slow-growing mycobacteria, we first generated a null mutant of \textit{M. tuberculosis} H37Rv \( nrp \) by using specialized transduction to replace \( nrp \) with a hygromycin resistance cassette. Subsequently, we generated a complemented strain (\( nrp \)-comp) by introducing an integrative shuttle cosmid vector (containing an \textit{M. tuberculosis} H37Rv cosmid fragment spanning \textit{Rv0096} to \textit{Rv0109}) into the \( \Delta nrp \) mutant (see Fig. S1A in the supplemental material). To control for possible polar effects of the \( \Delta nrp \) deletion on the adjacent gene \textit{Rv0102}, the expression of this gene was monitored in either of the recombinant \textit{M. tuberculosis} strains. We found that the expression patterns of \textit{Rv0102} were similar in mutant and complemented bacteria (Fig. S1B). Furthermore, the axenic growth of the two engineered \textit{M. tuberculosis} H37Rv strains was identical and similar to that of the wild-type (WT) H37Rv (Fig. S1C), showing no major growth defects imposed by the absence of \( nrp \). Additionally, the \( \Delta nrp \) strain retained its acid-fast properties (Fig. S1D).

To assess the role of \( nrp \) in the pathogenesis of \textit{M. tuberculosis} in the murine model of infection, immunocompetent (C57BL/6) mice were infected with aerosols of WT, \( \Delta nrp \), or \( nrp \)-comp strains of \textit{M. tuberculosis} H37Rv. Bacterial burdens in the lungs and spleens of infected mice were analyzed at different time points postinfection (Fig. 2A and B). At 3 weeks postinfection, fewer colonies of the \( \Delta nrp \) strain were found in infected lungs than of the WT or \( nrp \)-comp strains (Fig. 2A). However, the lung bacterial loads of all three strains were similar at later time points (Fig. 2A), indicating that the \( \Delta nrp \) strain eventually grew to a level comparable to that of the WT strain in the long term. The differences in bacterial loads in the spleen were stark between the strains, with considerably fewer bacteria cultured from the spleens of mice infected with the \( \Delta nrp \) strain (Fig. 2B). Furthermore, we observed a significant difference in the survival of mice infected with the different strains. While all mice in groups infected with WT or \( nrp \)-comp strains died prior to 325 days postinfection, those infected with the \( \Delta nrp \) strain survived for up to 700 days postinfection (Fig. 2C). Given that we were able to complement the growth phenotypes in C57BL/6 (Fig. 2A to C), we chose to focus our comparison of the \( \Delta nrp \) and \( nrp \)-comp strains for all further studies described below in an effort to limit the number of mice used in our experiments.

To further explore the growth kinetics of the \( \Delta nrp \) strain in the early stages of infection, we repeated the infection of C57BL/6 mice to monitor CFU levels in lungs from day 14 to up to 90 days postinfection. The difference in CFU between \( \Delta nrp \)-strain- and \( nrp \)-comp-strain-infected mice was readily visible on day 14 postinfection, corresponding to a 48-fold lower bacterial burden (1.683 \( \log_{10} \) average difference) in the case of mice infected with the \( \Delta nrp \) strain on day 20. From day 30 postinfection and up to day 90, the \( \Delta nrp \) strain reached lung bacillary counts comparable to those of the \( nrp \)-comp strain (Fig. 2D), as observed before (Fig. 2A).

**\( \Delta nrp \)-strain-infected mice develop less lung pathology.** In addition to the differences observed in the progression of bacterial burdens, a distinct phenotype was also observed in lung histopathological features during infection with the \( \Delta nrp \) strain versus the \( nrp \)-comp strain (Fig. 2E and F). Specifically, by day 20 postinfection, no discernible lesions were observed in the lungs of \( \Delta nrp \)-strain-infected animals, whereas multiple small inflammatory infiltrates were already present in the lungs of animals infected with the \( nrp \)-comp strain (Fig. 2E and F). This was likely due to the differences in bacterial burdens observed at this time point (Fig. 2D). By day 30 postinfection, the lesions in the lungs of mice infected with the \( nrp \)-comp strain were larger than those in mice infected with the \( \Delta nrp \) strain (Fig. 2E and F), even though both presented the same bacterial burden (Fig. 2D). Remarkably, the histological differences were maintained throughout the chronic stage of infection, as on day 90 postinfection, the
animals infected with the \( \Delta nrp \)-comp strain still presented a greater degree of pathology than those infected with the \( \Delta nrp \) strain (Fig. 2E and F), despite the fact that the bacterial burdens had been similar in both cases for 60 days (Fig. 2D). This subdued pathology may explain the longer survival of mice infected with the \( \Delta nrp \) strain (Fig. 2C).

**Kinetics of the immune response is altered in \( \Delta nrp \)-strain-infected mice.** So far, our data indicated that in the absence of \( nrp \), mice had a better ability to control the infection at initial time points and showed a striking lesser pathology even at late time points of infection. These findings suggest that a differential immune response may be occurring in the absence of Nrp function. To test this hypothesis, we next investigated the dynamics of immune cell populations elicited during infection with \( \Delta nrp \) or \( nrp \)-comp strains. We focused on myeloid (alveolar macrophages, inflammatory monocytes, and neutrophils) (Fig. 3A to C) and lymphoid (CD4\(^+\) T cells, CD8\(^+\) T cells, and B cells) (Fig. 3D to F) cells known to be relevant to the pathogenesis of TB. Whereas no substantial differences were found throughout the infection with either strain in...
alveolar macrophages (Fig. 3A), neutrophils (Fig. 3C), CD8^+ T cells (Fig. 3E), and B cells (Fig. 3F), significantly fewer inflammatory monocytes (Fig. 3B) and CD4^+ T cells (Fig. 3D) were detected at day 20 postinfection in the lungs of mice infected with the Δnrp strain. These differences were attenuated by day 30 postinfection and were no longer present.
by day 90 postinfection (Fig. 3B and D). In addition to the decreased numbers of inflammatory monocytes and CD4+ T cells observed 20 days postinfection in the absence of *nrp* expression, the number of activated cells within these populations, as measured by the expression of surface markers major histocompatibility complex (MHC) class II and CD44, was also decreased (Fig. 3G and H). The gating strategy using the definition of these populations is presented in Fig. S2.

At the molecular level, the diminished recruitment of inflammatory monocytes seen in the Δ*nrp* strain may be explained by a lower expression of CCL2 and CCL7, chemokines that play a role in the recruitment of myeloid cells to the site of infection (21), in the lungs of these animals (Fig. 3I). In line with a lower frequency of activated CD4+ T cells in Δ*nrp*-strain-infected animals, a decreased expression of gamma interferon (IFN-γ) was observed in the lungs of these animals compared to that in *nrp*-comp-strain-infected mice (Fig. 3I). Tumor necrosis factor (TNF), another inflammatory mediator during TB, is also expressed at a lower level upon infection with the Δ*nrp* strain (Fig. 3I).

In all, the absence of *nrp* function in *M. tuberculosis* improves the host’s ability to control bacterial growth early postinfection, which is reflected in a lower bacterial burden. This is accompanied by diminished inflammatory monocyte and CD4+ T cell recruitment and activation, as well as decreased expression of inflammatory mediators, which in the long-term likely lower the progression of lung pathology. Thus, these data suggest Nrp as a novel virulence factor for *M. tuberculosis*, altering the initial phases of infection and the immune response, but with a long-lasting impact on the pathology developed at the site of infection.

**Δ*nrp* mutant is attenuated for growth in immune-deficient mice.** Our findings point to a role for *nrp* during the early stages of *M. tuberculosis* infection. These findings led us to investigate for possible differences in the course of infection with Δ*nrp* or *nrp*-comp strains in immune-deficient mice. We first infected SCID mice with aerosols of WT H37Rv, Δ*nrp*, or *nrp*-comp strains and observed a remarkably longer survival rate for mice infected with the Δ*nrp* mutant (see Fig. S3). As with the above-described experiments performed with immunocompetent mice, given that the survival patterns were restored upon complementation, we performed all subsequent experiments with immunodefective mice using the Δ*nrp* and Δ*nrp*-comp strains. Next, we infected recombination activating 2 (RAG2)-deficient (−/−) mice and IFN-γ−/− mice. Both mouse strains are unable to control *M. tuberculosis* growth and typically succumb to infection 40 to 50 days after infection (22, 23). In line with this, both RAG2−/− and IFN-γ−/− mice succumbed to infection with the Δ*nrp* mutant (Fig. 4A and B). Strikingly, both mouse strains infected with the Δ*nrp* mutant registered a significantly higher survival rate (average survival of 114 days against 44.7 days in RAG2−/− mice and 99 days against 45 days in IFN-γ−/− mice). An analysis of lung CFU counts indicated that the Δ*nrp* mutant grew at a lower rate in the lungs of infected RAG2−/− mice (Fig. 4C). However, at the time of death, the lung bacterial burdens observed for each *nrp* strain were identical in both RAG2−/− (Fig. 4C) and IFN-γ−/− (Fig. 4D) animals. Furthermore, at the time of death, the lungs of RAG2−/− (Fig. 4E) and IFN-γ−/− (Fig. 4F) mice infected with the Δ*nrp* strain displayed significantly less pathology than their *nrp*-comp counterparts. Therefore, our data are indicative that in the absence of acquired immunity or IFN-γ, the attenuated *M. tuberculosis* growth due to the loss of *nrp* function was much more prolonged, associating again with reduced pathology. This set of data supports a more effective control of bacterial burden by the host’s innate immunity, in the presence of limited pathology, in the absence of *nrp* function.

**Primary macrophages are more efficient at controlling the growth of the Δ*nrp* strain.** Altogether, our findings suggest a more effective control of the Δ*nrp* strain by the host during the innate immune response. Since macrophages are one of the first types of cells to be infected by *M. tuberculosis* and to exert microbicidal functions (24), we questioned whether the expression of *nrp* impacted the bacterial control by infected macrophages. For this, we resorted to an *in vitro* system where mouse bone marrow-derived macrophages (BMDM) or macrophages isolated from the peritoneal
FIG 4 Growth of Δnrp mutant is attenuated in immune-deficient mice. C57BL/6 RAG2−/− (A, C, and E) and IFN-γ−/− (B, D, and F) mice were infected by aerosol exposure to a low dose of the Δnrp or nrp-comp strain. (A and B) The weights of the animals were monitored weekly up to day 30 and every 2 days thereafter to determine the survival curves. At the indicated time points (C) or at the time of death (D), the lungs of infected mice were collected and the bacterial burden was determined by CFU enumeration. The lung pathology was determined on day 40 postinfection for RAG2−/− (E) or at the time of death for IFN-γ−/− (F) animals. Shown are pictures from H&E staining for one animal representative of the experimental group; ×40 magnification. The initial bacterial burdens were log$_{10}$ 1.92 ± log$_{10}$ 0.069 and log$_{10}$ 1.701 ± log$_{10}$ 0.0707 (RAG2−/− experiment) and log$_{10}$ 1.92 ± log$_{10}$ 0.069 and log$_{10}$ 1.748 ± log$_{10}$ 0.0707 (IFN-γ−/− experiment) for Δnrp and nrp-comp strains, respectively. BMDM (G and H) or pMac (G) were infected with Δnrp or nrp-comp strains at an MOI of 1 in the absence (G) or presence (H) of exogenous IFN-γ. On day 4 postinfection, the intracellular bacterial load was determined by CFU enumeration. Data are shown as the means ± SEMs from 8 independent animals (A to F) or from 6 replicate wells in 2 independent experiments (G and H). Statistical analysis was performed with log-rank (Mantel-Cox) tests for the Kaplan-Meier curves (A and B) or two-way ANOVAs using Sidak’s tests for multiple comparisons (C to H). *, *P < 0.05; ***, *P < 0.001; ****, *P < 0.0001.
cavity (pMac) were infected with either of the strains, and the intracellular bacterial burden was assessed 96 h later. This time point ensured macrophage viability, thus avoiding the phenotypes related to cell death, rather than intracellular bacterial growth. The growth of the nrp-comp strain at this time point, in either of the macrophage types, was higher than that observed for the Δnrp strain (Fig. 4G). We then investigated the impact of exogenous IFN-γ on the ability of BMDM to control the nrp-deficient and -complemented M. tuberculosis strains. Exogenous IFN-γ improved the control of either of the strains by the macrophages, ablating the differences observed in bacterial growth (Fig. 4H). Of note, the macrophages infected with either of the M. tuberculosis strains showed similar patterns of cell viability and of cytokine production (see Fig. S4), suggesting a specific phenotype linked to bacterial control in the absence of Nrp. Altogether, these data support a virulence-associated role for Nrp in M. tuberculosis infection during the initial interaction with host macrophages. However, intriguingly, once the macrophages become fully activated, the host advantage over the Δnrp M. tuberculosis strain was lost. These in vitro findings are in line with the in vitro data, where the attenuation of the nrp-deficient M. tuberculosis strain is particularly notable during the early phase of infection but lost once the acquired immune response is established.

**DISCUSSION**

TB remains a devastating disease to mankind, with high human and economic tolls (25, 26). To efficiently tackle TB, an improvement of several current tools is needed, notably with regard to prevention, diagnosis, and treatment. Owing to the alarming drug resistance rates, which caused 480,000 cases of complicated TB in 2016 (1), there is a pressing need for the development of novel treatment strategies. In this context, a clearer understanding of the key virulence factors in M. tuberculosis may help in finding new vulnerable and druggable targets. Different experimental approaches have been pursued for the identification of essential M. tuberculosis genes (2, 4, 16), including target-based screening. In this study, we aimed at elucidating the role of the nrp gene in the pathogenesis of TB, resorting to a genetically engineered nrp-deficient mutant M. tuberculosis strain, as well as in vitro and in vivo models of infection. Previous studies reporting that the nrp gene harbored by M. tuberculosis is essential for in vivo growth (16) and expressed during early time points postinfection (18) support a role for the cryptic metabolite produced by Nrp during infection. Furthermore, our in silico analysis showed that nrp is part of a cluster of genes that is rare among the mostly nonpathogenic rapid-growing NTMs and highly conserved among the slow-growing pathogenic species of the genus Mycobacterium. Overall, these findings support a role for the product of the nrp cluster in the pathogenesis of infection by Mycobacterium species.

A previous screen aimed at finding M. tuberculosis persistence mutants in isoniazid-treated mice identified a transposon mutant with an insertion upstream of Rv0097, a gene encoding a putative oxoreductase and possibly also involved in the biosynthesis pathway of the cryptic metabolite associated with nrp (17). The infection of WT mice through an intravenous route showed that the transposon mutant was attenuated in lungs and spleen (17). This former study thus supports the notion that one or more genes in the Rv0096-Rv0101 cluster play a role in survival during in vivo infection. In addition to the findings obtained with the transposon mutant (17), the study presented herein characterizes this operon in a more thorough way from in silico to biological data. Indeed, by using the aerosol route of infection, we show that the nrp cluster is associated not only with a better transient control but also with altered lung pathologies and demonstrate its ability to cause delayed mortality in infected immunocompetent mice. Accordingly, we show that in immunocompetent hosts, the nrp-deficient M. tuberculosis strain showed a delayed growth pattern in the lungs during the first 20 days of infection compared to that of its WT H37Rv and complemented counterparts. This delay in growth at the site of infection was accompanied by the delayed dissemination of the nrp-deficient M. tuberculosis strain to the spleens of the infected
infection in immunodeficient hosts. We were surprised to discover that RAG2 from the observation that the lack of this gene highly attenuates M. tuberculosis. This early role for Nrp during infection fits with a previous report showing that the in vivo expression of nrp is restricted to the early phases of infection (18). Accompanying the lower bacterial burden in the lungs of M. tuberculosis Δnrp-infected mice, we found a delayed recruitment and activation of inflammatory monocytes and CD4 T cells. However, the recruitment of other immune cell populations was similar between the two infections, possibly suggesting that the differences observed for inflammatory monocytes and CD4 T cells did not result solely from the reduced bacterial burdens upon M. tuberculosis Δnrp infection. The differential course of infection in terms of dissemination and pathology caused by the M. tuberculosis Δnrp strain may be linked to the differential recruitment of inflammatory monocytes. Previous studies showed that the induction of CCL2 during mycobacterial infection is associated with the recruitment of permissive monocytes to the lesion, which then support bacterial growth (21, 29). It is interesting to speculate that, as in the absence of nrp, CCL2 induction is lower and fewer permissive monocytes are recruited, and so a lower bacterial burden and less dissemination are observed. On day 30 postinfection, these differences are lost, and similar numbers of inflammatory monocytes are present in the lungs of mice infected with either of the M. tuberculosis strains.

The most notable and interesting finding on the role of nrp in TB pathogenesis came from the observation that the lack of this gene highly attenuates M. tuberculosis infection in immunodeficient hosts. We were surprised to discover that RAG2−/−, SCID−/−, and IFN-γ−/− mice infected with the M. tuberculosis Δnrp strain survived substantially longer than those infected with the complemented counterpart. As shown in the case of the RAG2−/− mice, the growth of M. tuberculosis Δnrp over time was much slower than that of the complemented strain. This suggests that in the absence of acquired immunity, the growth of M. tuberculosis Δnrp remains in check, to the benefit of the host. A similar result is inferred from the infection of IFN-γ−/− mice, as the bacterial burdens at the time of death were comparable between M. tuberculosis Δnrp and its complemented counterpart. Most importantly, independent of the genetics of the mouse host, the lung pathology resulting from infection with M. tuberculosis Δnrp was much less exuberant that that observed for the complemented strain. The bacterial burden phenotype of the M. tuberculosis Δnrp strain is most likely mediated by the bacterial interaction with the macrophage. Indeed, we showed that primary mouse macrophages control the bacterial growth more efficiently when nrp is absent. However, the mechanistic bases of this better control remain unknown but do not seem to depend on the altered production of, at least, TNF, interleukin 1β (IL-1β), and interleukin 10 (IL-10). Further studies, perhaps encompassing global transcriptional analysis, are thus required to further explore this observation.

In all, our findings highlight a role for the nrp cluster in evading the basic microbicial mechanisms of the macrophage, which is then overcome by the adaptive immune response. It is tempting to speculate that the mechanisms that enable this result from host-pathogen coevolution events. Several outstanding questions arise from this study: which is the mechanism hijacked by Nrp at the level of innate immunity? How does the acquired immune response abrogate the impact of Nrp in the macrophage? As an answer to these questions, the infection of mice deficient for Toll-like receptor 2 (TLR2), TLR4, IL-10, arachidonate 5-lipoxygenase (ALOX5), or arachidonate 15-lipoxygenase (ALOX15) with the M. tuberculosis Δnrp strain showed the same phenotype as WT mice.
(see Fig. S5 in the supplemental material). Therefore, basic recognition mechanisms, as well as an imbalanced anti-inflammatory response, do not seem to be associated with the npr phenotype. The precise metabolite produced by the npr cluster in M. tuberculosis remains unidentified, as we were unable to detect an npr-related metabolite in lab-grown cultures of M. tuberculosis, and future efforts will likely focus on the identification of the product ex vivo in infected tissue. Though challenging, these experiments will enlighten the biological role of the npr cluster as well as the best timing to target it from a therapeutic point of view. Despite the importance of pursuing these questions in the future, our study provides strong evidence linking the npr cluster to M. tuberculosis attenuation, specifically in the context of an immunocompromised host. Considering the huge impact of the HIV epidemics on TB, our data call for immediate efforts to be put toward a further understanding of the biological role of Nrp and the development of therapies targeted to immunocompromised TB patients.

MATERIALS AND METHODS

Comparative genomics. Sequence identity scores were obtained by using the BLAST+ 2.6.0 (30) application to search a local database of 72 genomic sequences from species selected to be representative of the phylogeny of the genus Mycobacterium (19) (NZ_LQOM00000000, NZ_LQQ00000000, NZ_LQOR00000000, NZ_LQSO00000000, NZ_LQT00000000, NZ_LQYO00000000, NZ_ARBU00000000, NZ_LQPB00000000, NZ_LQPP00000000, NZ_ADNV00000000, NZ_LQPO00000000, NZ_MHDD00000000, NZ_LQA00000000, CP000480, GCA_000243415.3_ASM24341v3, GCA_002102065.1_ASM210206v1, NC_000962, NC_002677, NC_008595, NC_008611, NC_008726, NC_008727, NC_008728, NC_010397, NC_010612, NC_018148, NC_015564, NC_015576, NC_015758, NC_015848, NC_016604, NC_016605, NC_016946, NC_018027, NC_018562, NC_019966, NC_020133, NC_021715, NC_022663, NZ_AGVE00000000, NZ_AIF00000000, NZ_AKPD00000000, NZ_CCBF00000000, NZ_CPO007220, NZ_CPO011269, NZ_CPO11491, NZ_CPO11530, NZ_CP004475, NZ_CP015278, NZ_CP020821, NZ_CSTD00000000, NZ_LQJ00000000, NZ_LQJO00000000, NZ_LQKV00000000, NZ_LQOW00000000, NZ_LQOX00000000, NZ_LQZO00000000, NZ_LQPC00000000, NZ_LQPD00000000, NZ_LQPE00000000, NZ_LQPF00000000, NZ_LQPG00000000, NZ_LQPH00000000, NZ_LQPO00000000, NZ_LQPS00000000, NZ_LQPT00000000, NZ_LQPU00000000, NZ_LQPV00000000, and NZ_LQPW00000000). The database was queried using the sequence of the npr cluster (Rv0097-Rv0101) from H37Rv (NC_000962.3). The sequence identity score was calculated by combining the query coverage, E value, and identity values for each hit with the weights 0.5, 0.25, and 0.05, respectively. A multiple-genome alignment of the sequences NC_002677 (M. leprae), NC_015848 (Mycobacterium canettii), NC_002945 (Mycobacterium bovis) and NC_000962 (M. tuberculosis) was performed using Mauve 2.4.0 (31). The level of nucleotide diversity (r) was calculated with MEGA7.1.0 (32) using multiple-sequence alignments of 220 genomic sequences from MTBC strains (lineages 1 to 7) (20).

Construction of a M. tuberculosis H37Rv npr null mutant. A null mutant of M. tuberculosis H37Rv npr (Rv0101) was generated by Specialized Transduction using previously described protocols (33, 34). Briefly, a derivative of temperature sensitive phage phAE159 was constructed to replace npr (phΔnpr) with a hygromycin resistance gene (hyg). Hygromycin resistant colonies obtained following transduction of M. tuberculosis H37Rv were verified by Southern blot to confirm the chromosomal replacement of npr with hyg. One such transductant was termed Δnpr and used in all subsequent experiments.

Generation of an npr-complemented strain. A 28-kb M. tuberculosis H37Rv cosmid fragment (spanning genomic position bp 104933 to bp 133536) was packaged in the integrative shuttle cosmid vector pYUB412-Kan to generate pYUB2420. This recombinant cosmid spans a region that extends from Rv0096 to Rv0109. pYUB2420 was introduced into the Δnpr strain by electroporation, and six kanamycin-resistant transformants were confirmed by Southern blot to contain chromosomally integrated pYUB2420. One of these transformants, termed Δnpr-comp, was selected for further studies.

Bacterial growth and stocks. Bacteria were grown in Middlebrook 7H9 liquid medium (BD Biosciences) supplemented with 0.05% Tween 80, 0.2% glycerol, and 10% oleic acid-albumin-dextrose-catalase (OADC) for 7 to 10 days and then subcultured in Proskauer Beck (PB) medium supplemented with 0.05% Tween 80 and 2% glycerol to the mid-log phase. Bacterial stocks were aliquoted and frozen at −80°C. To determine the concentration of M. tuberculosis in aliquots, 6 frozen aliquots were serial diluted and plated on Middlebrook 7H11 (BD Biosciences) agar plates supplemented with 10% OADC and 0.5% glycerol. Viable bacteria were determined by CFU enumeration after 21 to 28 days of incubation at 37°C.

Ethics statement. All animal experiments were performed in strict accordance with the recommendations of the European Union Directive 2010/63/EU. All experimental procedures were approved by the local animal ethics committee, and licensed by the Portuguese National Authority for Animal Health (DGAV, Portugal) with reference number 014811/2016-07-13. Animal procedures were conducted by laboratory personnel with accreditation for animal research given by DGAV. The mice were euthanized by CO2 inhalation, with efforts to minimize suffering.

Mouse strains. C57BL/6 mice were purchased from Charles River Laboratory (Barcelona, Spain). Rag2-deficient mice were purchased from Instituto Gulbenkian de Ciência (IGC) or generously provided by Margarida Correia-Neves (ICVS), and IFN-γ deficient mice were generously provided Susana Roque (ICVS). All transgenic mice were of a C57BL/6 genetic background. SCID mice were obtained from Charles River Laboratory (USA).
**Experimental infection.** Mice were infected with *M. tuberculosis* H37Rv (WT), Δ*nrp*, or Δ*nrp*-comp strains via the aerosol route by using an inhalation exposure system (Glas-Col), according to previously published protocols (35, 36), which resulted in the delivery of 100 to 200 viable bacteria to the lungs.

**Survival.** The weights of the infected mice were determined every week after infection for immunocompetent mice and every week after infection for the first 30 days and every 48 h from day 30 postinfection onwards for immunodeficient hosts. Mice were humanely euthanized if they lost 20% of their maximum weight or upon losing responsiveness to physical stimulation. Whenever possible, the lungs of moribund animals were harvested for histology and bacterial burden assessment.

**Organ processing.** At the indicated time points postinfection, the mice were euthanized by CO$_2$ asphyxiation, and the organs were aseptically excised and processed as described previously (35, 36). Brieﬂy, the lungs were perfused by applying 10 ml phosphate-buffered saline (PBS) through the right ventricle of the heart to flush blood cells, and single-cell suspensions were prepared in complete Dulbecco’s modiﬁed Eagle medium (cDMEM; DMEM supplemented with 10% fetal bovine serum [FBS], glutamine, HEPES, and sodium pyruvate, all from Gibco). Single-cell suspensions were used for bacterial burden determination, flow cytometry analysis, and RNA extraction. The number of cells was counted using a Countess automated cell counter (Life Technologies).

**Bacterial burden determination.** The assessment of initial bacterial burden was performed 3 days postinfection by growing viable bacteria from whole-lung homogenates. For the other time points, lung and spleen single-cell suspensions were incubated with 0.1% saponin (Sigma-Aldrich) for 10 min to release intracellular bacteria. The CFU was determined by plating 10-fold serial dilutions of saponin-treated cell suspensions on Middlebrook 7H11 agar plates as described in "Bacterial growth and stocks." BBL MGIT PANTA antibiotic mixture (BD Bioscience) was added to prevent the contamination of lung samples. Viable *M. tuberculosis* colonies were counted after 21 to 28 days of incubation at 37°C.

**Flow cytometry.** Lung cells (1 × 10$^5$ to 2 × 10$^5$) were stained for surface antigens for 30 min at 4°C. Stained cells were washed and then fixed overnight in PBS containing 2% paraformaldehyde. The following antibodies were used: CD3-PE (clone 145-2C11; eBioscience), CD4-PE (clone RM4-5; eBioscience), CD8-APC (clone 5H10-1; BioLegend), CD44-PerCP/Cy5.5 (clone 1M7; eBioscience), CD62L-PECy7 (clone MEL-14; BioLegend), CD19-APC (clone eBio1D3; eBioscience), Ly6G-APC (clone 1A8; BioLegend), Ly6C-PerCP/Cy5.5 (clone AL-21; BD Pharmingen), MHC II-FITC (clone AMS-32.1; BD Pharmingen), CD11b-PE (clone M1/70; BioLegend), and CD11c-PE (clone N418; BioLegend). Samples were run on an LSRII flow cytometer with Diva software, and the data were analyzed using FlowJo version 10.1.r7 software. The total number of cells in each gate was calculated using the total number of cells determined by the Countess automated cell counter. The gating strategy used is shown in Fig. S2 in the supplemental material.

**RNA extraction, reverse transcription, and real-time PCR.** Total RNA from infected lungs was extracted with TRIzol reagent (Invitrogen), and cDNA was synthesized and analyzed by real-time PCR, as described previously (35, 36). Target IFN-γ and TNF mRNA expression was quantified using SYBR green (GriS) and specific oligonucleotides and normalized to the ubiquitin mRNA levels. The expression of CCL2 and CCL7 was quantitated using specific primer-probe sets (Applied Biosystems) and normalized to the expression of hypoxanthine phosphoribosyltransferase (HPRT). Target IFN-γ and TNF mRNA expression was quantified using SYBR green (GriS) and specific oligonucleotides and normalized to the ubiquitin mRNA levels. The expression of CCL2 and CCL7 was quantitated using specific primer-probe sets (Applied Biosystems) and normalized to the expression of hypoxanthine phosphoribosyltransferase (HPRT).

**Histology analysis.** The right upper lobes of the lungs were ﬁxed in PBS containing 3.7% formaldehyde, embedded in parafﬁn, sectioned in 2- to 3-μm-thick slices, and stained with hematoxylin-eosin (35). The lung surface area of inﬂammation was measured using ImageJ software (version 1.50e; NIH). The percentage of total lung area involved with inﬂammation was calculated by dividing the cumulative area of inﬂammation by the total lung surface area for each sample.

**Infection of bone marrow-derived macrophages and peritoneal macrophages.** BMDM were differentiated from bone marrow cells obtained from the femurs and tibiae of C57BL/6 mice and cultured in the presence of L-cell conditioned medium, as described previously (37). pMac were obtained by intraperitoneally injecting 1 ml of thioglycolate into WT C57BL/6 mice. After 4 days, the mice were euthanized and the peritoneums were washed with PBS. In both cases, 1 × 10$^6$ cells were infected with Δ*nrp* or Δ*nrp*-comp strains at a multiplicity of infection (MOI) of 1 bacteria to 1 macrophage. Four hours after infection, the cells were washed 4 times with PBS (Gibco) to remove extracellular bacteria. The adherent cells were cultured at 37°C in 1 ml of cDMEM in the presence or absence of 100 U/ml of IFN-γ for 96 h. Four or ninety-six hours postinfection, 0.1% saponin (Sigma-Aldrich) in PBS was added to the wells, and the cells were incubated at room temperature (RT) for 10 min to release intracellular bacteria. The number of viable bacteria was determined by plating 10-fold serial dilutions of the saponin-treated cell suspensions on supplemented Middlebrook 7H11 agar, as described in "Bacterial growth and stocks." Cytokine determination by ELISA. TNF, IL-1β, and IL-10 concentrations in the supernatants of infected macrophages were determined 24 h postinfection by enzyme-linked immunosorbent assays (ELISAs) with commercially available kits (eBioscience), according to the manufacture’s instructions. Cytokine levels from uninfected cells were below the assay level of detection (not shown).

**Cell viability assay.** Cell viability was determined in noninfected or infected macrophages 2 or 4 days postinfection. Macrophages were gently detached from low-adherence tissue culture plates using a cell scraper. Cell viability was assessed by using trypan blue exclusion.

**Statistical analysis.** Data were analyzed using GraphPad Prism 6. The differences between groups were analyzed with two-way analyses of variance (ANOVA) using Sidak’s tests for multiple comparisons. Kaplan-Meier survival curves were analyzed with the log-rank (Mantel-Cox) test. Differences were considered significant at *P* values of *<*0.05.
ACKNOWLEDGMENTS

We thank the animal facility personnel for their excellent help. K.B. and H.M. designed and performed the experiments and wrote the manuscript; N.O. performed the in silico analysis and wrote the manuscript; J.S., F.C., C.M., B.C., M.C., J.K., A.S., and C.M.F. performed the experiments; A.G.C., E.T., and W.R.J. discussed the data and wrote the manuscript; and A.B. and M.S. designed the experiments, discussed the data, and wrote the manuscript. The authors declare no conflict of interest. M.S. is an Associate Foundation for Science and Technology (FCT) investigator.

A.B. and M.S. received collaborative grant support from a Royal Society International Exchanges grant. This article is a result of the project Norte-01-0145-FEDER-000012 structured program on bioengineered therapies for infectious diseases and tissue regeneration, and project Norte-01-0145-FEDER-000013, supported by Norte Portugal Regional Operational Program (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (FEDER). N.O. received funding from FEDER, through the Competitiveness Factors Operational Program (COMPETE), and national funds, through the FCT, under the scope of the project POCI-01-0145-FEDER-007038, and from IF/00474/2014. W.R.J. received grant support from the National Institutes of Health (NIH; grant no. AI26170). A.B. has received funding from the Medical Research Council (UK) for work leading up to this project. The funders had no role in the project design.

REFERENCES

1. World Health Organization. 2017. Global tuberculosis control. World Health Organization, Geneva, Switzerland.
2. DeJesus MA, Gerrick ER, Xu W, Park SW, Long JE, Boutte CC, Rubin EJ, Schnappinger D, Ehr T, Fortune SM, Sassetti CM, Ioerger TR. 2017. Comprehensive essentiality analysis of the Mycobacterium tuberculosis genome via saturating transposon mutagenesis. mBio 8:e02133-16. https://doi.org/10.1128/mBio.02133-16.
3. Sassetti CM, Boyd DH, Rubin EJ. 2003. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48:77–84. https://doi.org/10.1046/j.1365-2958.2003.03425.x.
4. Singh AK, Carette X, Potluri LP, Sharp JD, Xu R, Prisic S, Husson RN. 2016. Investigating essential gene function in Mycobacterium tuberculosis using an efficient CRISPR interference system. Nucleic Acids Res 44:e143. https://doi.org/10.1093/nar/gkw625.
5. Walsh CT. 2016. Insights into the chemical logic and enzymatic machinery of NRPS assembly lines. Nat Prod Rep 33:127–135. https://doi.org/10.1039/C5RP00035A.
6. Weissman JI. 2015. The structural biology of biosynthetic megaenzymes. Nat Chem Biol 11:660–670. https://doi.org/10.1038/nchembio.1883.
7. Billman-Jacobe H, McConville MJ, Haite R, Kovacevic S, Coppel RL. 1999. Identification of a peptide synthetase involved in the biosynthesis of glycopeptidolipids of Mycobacterium smegmatis. Mol Microbiol 33:1244–1253.
8. Quadri LE, Sello J, Keating TA, Weinreb PH, Walsh CT. 1998. Identification of a Mycobacterium tuberculosis gene cluster encoding the biosynthetic enzyme for assembly of the virulence-confering siderophore mycobactin. Chem Biol 5:31–45. https://doi.org/10.1016/S1070-4971(98)90291-5.
9. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream M-A, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537–544. https://doi.org/10.1038/31159.
10. Chhabra A, Haque AS, Pal RK, Goyal A, Rai R, Joshi S, Panjikar S, Pasha S, Sankaranarayanan R, Gokhale RS. 2012. Nonprocessive [2 + 2]e− off-loading reductase domains from mycobacterial nonribosomal peptide synthetases. Proc Natl Acad Sci U S A 109:5681–5686. https://doi.org/10.1073/pnas.1118680109.
11. Haque AS, Patel KD, Deshmukh MV, Chhabra A, Gokhale RS, Sankaranarayanan R. 2014. Delineating the reaction mechanism of reductase domains of nonribosomal peptide synthetases from mycobacteria. J Struct Biol 187:207–214. https://doi.org/10.1016/j.jsb.2014.07.008.
12. Maiya K, Bajaj P, Surolia N, Surolia A, Suguna K. 2012. Insights into the substrate specificity of a thioesterase Rv0098 of Mycobacterium tuberculosis through X-ray crystallographic and molecular dynamics studies. J Biomol Struct Dyn 29:973–983. https://doi.org/10.1080/07391102.2012.10507417.
13. Wang F, Langley R, Gulten G, Wang L, Sacchettini JC. 2007. Identification of a type III thioesterase reveals the function of an operon crucial for Mtbo virulence. Chem Biol 14:543–551. https://doi.org/10.1016/j.chembiol.2007.04.005.
14. Harris NC, Sato M, Herman NA, Twigg F, Cai W, Liu J, Zhu X, Downey J, Khalaf R, Martin J, Koshino H, Zhang W. 2017. Biosynthesis of isonicotinamide lipopeptides by conserved nonribosomal peptide synthetase gene clusters in Actinobacteria. Proc Natl Acad Sci U S A 114:7025–7030. https://doi.org/10.1073/pnas.1705016114.
Bhatt et al.

15. Sassetti CM, Boyd DH, Rubin EJ. 2001. Comprehensive identification of conditionally essential genes in mycobacteria. Proc Natl Acad Sci U S A 98:12712–12717. https://doi.org/10.1073/pnas.231275498.

16. Sassetti CM, Rubin EJ. 2003. Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci U S A 100:12989–12994. https://doi.org/10.1073/pnas.2134250100.

17. Dhar N, McKinney JD. 2010. Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice. Proc Natl Acad Sci U S A 107:12275–12280. https://doi.org/10.1073/pnas.10103219107.

18. Kruh NA, Trought J, Izzo A, Prenni J, Dobos KM. 2010. Portrait of a pathogen: the Mycobacterium tuberculosis proteome in vivo. PLoS One 5:e13938. https://doi.org/10.1371/journal.pone.0013938.

19. Fedrizzi T, Meehan CJ, Grottola A, Giacobazzi E, Fregni Serpini G, Tagliazucchi S, Fabio A, Bettua C, Bertorelli R, De Sanctis V, Rumpianesi F, Pecorari M, Jousson O, Tortoli E, Segata N. 2017. Genomic characterization of non-tuberculous mycobacteria. Sci Rep 7:45258. https://doi.org/10.1038/srep45258.

20. Comas I, Coscolla M, Luo T, Borrell S, Holt KE, Kato-Maeda M, Parkhill J, Malla B, Berg S, Thwaites G, Yeboah-Manu D, Bothamley G, Mei J, Wei L, Bentley S, Harris SR, Niemann S, Diel R, Assefa A, Gao Q, Young D, Gagneux S. 2013. Out-of-Africa migration and neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet 45:1176–1182. https://doi.org/10.1038/ng.2744.

21. Cambier CJ, O’Leary SM, O’Sullivan MP, Keane J, Ramakrishnan L. 2017. Phenolic glycolipid facilitates mycobacterial escape from microbicidal tissue-resident macrophages. Immunity 47:552.e4–565.e4. https://doi.org/10.1016/j.immuni.2017.08.003.

22. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. 1993. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178:2234–2247. https://doi.org/10.1084/jem.178.6.2234.

23. Nandi B, Behar SM. 2011. Regulation of neutrophils by interferon-gamma limits lung inflammation during tuberculosis infection. J Exp Med 208:2251–2262. https://doi.org/10.1084/jem.20110919.

24. Schorey JS, Schlesinger LS. 2016. Innate immune responses to tuberculosis. Microbiol Spectr 4:TBTB2-0010-2016. https://doi.org/10.1128/microbiolspec.TBTB2-0010-2016.

25. Raviglione M, Sulis G. 2016. Tuberculosis 2015: burden, challenges and conditions for control and elimination. Infect Dis Rep 8:12712–12717. https://doi.org/10.1073/pnas.231275498.

26. Kruh NA, Trought J, Izzo A, Prenni J, Dobos KM. 2010. Portrait of a pathogen: the Mycobacterium tuberculosis proteome in vivo. PLoS One 5:e13938. https://doi.org/10.1371/journal.pone.0013938.

27. Cooper AM, Torrado E. 2012. Protection versus pathology in tuberculosis: recent insights. Curr Opin Immunol 24:431–437. https://doi.org/10.1016/j.coi.2012.04.008.

28. Dorhoi A, Kaufmann SH. 2016. Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis. Semin Immunopathol 38:153–166. https://doi.org/10.1007/s00281-015-0531-3.

29. Cambier CJ, Takaki KK, Larson RP, Hernandez RE, Tobin DM, Urdahl KB, Cosma CL, Ramakrishnan L. 2014. Mycobacteria manipulate macrophage recruitment through coordinated use of membrane lipids. Nature 505:218–222. https://doi.org/10.1038/nature12799.

30. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. 2009. BLAST+: architecture and applications. BMC Bioinformatics 10:421. https://doi.org/10.1186/1471-2105-10-421.

31. Darling AC, Mau B, Blattner FR, Perna NT. 2004. Mauve: multiple alignment of conserved genomic sequence with rearrangements. Genome Res 14:1394–1403. https://doi.org/10.1101/gr.2289704.

32. Kumar S, Stecher G, Tamura K. 2016. MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. Mol Biol Evol 33:1870–1874. https://doi.org/10.1093/molbev/msw054.

33. Bardarov S, Bardarov S, Jr, Pavelka MS, Jr, Sambandamurthy V, Larsen M, Tufariello J, Chan J, Hattfull G, Jacobs WR, Jr. 2002. Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. Microbiology 148:3007–3017. https://doi.org/10.1099/00221287-148-10.3007.

34. Jain P, Hsu T, Arai M, Biermann K, Thaler DS, Nguyen A, Gonzalez PA, Tufariello JM, Kriaikov J, Chen B, Larsen MH, Jacobs WR, Jr. 2014. Specialized transduction designed for precise high-throughput unmarked deletions in Mycobacterium tuberculosis. mBio 5:e01245-14. https://doi.org/10.1128/mBio.01245-14.

35. Cardoso F, Castro F, Moreira-Teixeira L, Sousa J, Torrado E, Silvestre R, Castro AG, Saraiva M, Pais TF. 2015. Myeloid sirtuin 2 expression does not impact long-term Mycobacterium tuberculosis control. PLoS One 10:e0131904. https://doi.org/10.1371/journal.pone.0131904.

36. Cruz A, Torrado E, Carmona J, Fraga AG, Costa P, Rodrigues F, Appelberg R, Correia-Neves M, Cooper AM, Saraiva M, Pedrosa J, Castro AG. 2015. BCG vaccination-induced long-lasting control of Mycobacterium tuberculosis correlates with the accumulation of a novel population of CD4+ IL-17+TNF-IL-2+ T cells. Vaccine 33:85–91. https://doi.org/10.1016/j.vaccine.2014.11.013.

37. Carmona J, Cruz A, Moreira-Teixeira L, Sousa C, Sousa J, Osorio NS, Saraiva AL, Svensson S, Kallenius G, Pedrosa J, Rodrigues F, Castro AG, Saraiva M. 2013. Mycobacterium tuberculosis strains are differentially recognized by TLRs with an impact on the immune response. PLoS One 8:e67277. https://doi.org/10.1371/journal.pone.0067277.